Precision BioSciences, Inc. (DTIL)Healthcare | Biotechnology | Durham, United States | NasdaqCM
8.59 USD
-0.17
(-1.941%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:37 a.m. EDT
The long-term outlook is catastrophic due to a brutal six-year decline where the stock has lost nearly 99% of its value, driven by four consecutive years of negative annual returns. Despite a massive spike in reported revenue growth, the company remains deeply unprofitable with negative operating cash flow and a negative return on equity, indicating that top-line expansion is not translating into sustainable business quality. The balance sheet, while showing low debt relative to equity, is propped up by a current ratio of 14x which masks the reality of burning cash without earnings. The short-term chart shows a recent bounce off the lows, but the statistical forecast model predicts a further decline over the next 45 days, and options flow confirms this bearish sentiment with heavy put positioning at the $5 strike. This is a speculative biotech play on a single pipeline event, not an investment in a functioning business. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.080987 |
| AutoTheta | 0.104453 |
| AutoETS | 0.114169 |
| AutoARIMA | 0.114173 |
| MSTL_57 | 0.123128 |
| MSTL_115 | 0.276561 |
| MSTL_57_115 | 0.297877 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 7.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 0.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 37.406 |
| Revenue per Share | 2.705 |
| Market Cap | 221,641,312 |
| Forward P/E | -4.54 |
| Beta | 1.25 |
| Profit Margins | -96.73% |
| Website | https://precisionbiosciences.com |
As of July 11, 2026, 5:37 a.m. EDT: Speculators are positioning for a significant downside move in the near term. Put open interest is heavily concentrated at the $5.00 strike for the July expiration, creating a dense wall of resistance just below current prices. While there is some call activity at the $10.00 level, the volume of puts suggests a 'bear put spread' or hedging strategy targeting a drop to the $5 range rather than a bullish breakout attempt.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9303371 |
| Address1 | 302 East Pettigrew St. |
| Address2 | Suite A-100 |
| All Time High | 710.1 |
| All Time Low | 3.53 |
| Ask | 10.59 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 703,440 |
| Average Daily Volume3 Month | 404,501 |
| Average Volume | 404,501 |
| Average Volume10Days | 703,440 |
| Beta | 1.251 |
| Bid | 6.15 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.949 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.59 |
| Current Ratio | 14.016 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 8.685 |
| Day Low | 8.26 |
| Debt To Equity | 37.406 |
| Display Name | Precision BioSciences |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -37,739,000 |
| Ebitda Margins | -0.83729 |
| Enterprise To Ebitda | -3.946 |
| Enterprise To Revenue | 3.304 |
| Enterprise Value | 148,923,296 |
| Eps Current Year | -2.48667 |
| Eps Forward | -1.89333 |
| Eps Trailing Twelve Months | -2.17 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 480 393 5553 |
| Fifty Day Average | 7.3372 |
| Fifty Day Average Change | 1.2528 |
| Fifty Day Average Change Percent | 0.17074633 |
| Fifty Two Week Change Percent | 93.03371 |
| Fifty Two Week High | 9.62 |
| Fifty Two Week High Change | -1.0299997 |
| Fifty Two Week High Change Percent | -0.10706858 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 5.0600004 |
| Fifty Two Week Low Change Percent | 1.4334279 |
| Fifty Two Week Range | 3.53 - 9.62 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,553,779,800,000 |
| Float Shares | 20,005,256 |
| Forward Eps | -1.89333 |
| Forward P E | -4.53698 |
| Free Cashflow | -21,668,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 66 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 45,073,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0644 |
| Held Percent Institutions | 0.65859 |
| Implied Shares Outstanding | 25,802,247 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,707,868,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. |
| Long Name | Precision BioSciences, Inc. |
| Market | us_market |
| Market Cap | 221,641,312 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_41018856 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -44,485,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 221,641,301 |
| Number Of Analyst Opinions | 5 |
| Open | 8.63 |
| Operating Cashflow | -58,728,000 |
| Operating Margins | -0.83733004 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 919 314 5512 |
| Previous Close | 8.76 |
| Price Eps Current Year | -3.454419 |
| Price Hint | 2 |
| Price To Book | 2.912852 |
| Price To Sales Trailing12 Months | 4.9173856 |
| Profit Margins | -0.96732 |
| Quick Ratio | 13.563 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -1.94064 |
| Regular Market Day High | 8.685 |
| Regular Market Day Low | 8.26 |
| Regular Market Day Range | 8.26 - 8.685 |
| Regular Market Open | 8.63 |
| Regular Market Previous Close | 8.76 |
| Regular Market Price | 8.59 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 705,507 |
| Return On Assets | -0.18222 |
| Return On Equity | -0.70927 |
| Revenue Growth | 372.724 |
| Revenue Per Share | 2.705 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 25,802,247 |
| Shares Percent Shares Out | 0.088999994 |
| Shares Short | 2,296,663 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,674,296 |
| Short Name | Precision BioSciences, Inc. |
| Short Percent Of Float | 0.091400005 |
| Short Ratio | 4.54 |
| Source Interval | 15 |
| State | NC |
| Symbol | DTIL |
| Target High Price | 60.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 29.6 |
| Target Median Price | 20.0 |
| Total Cash | 101,184,000 |
| Total Cash Per Share | 3.922 |
| Total Debt | 28,466,000 |
| Total Revenue | 45,073,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.880425 |
| Two Hundred Day Average Change | 2.7095752 |
| Two Hundred Day Average Change Percent | 0.4607788 |
| Type Disp | Equity |
| Volume | 705,507 |
| Website | https://precisionbiosciences.com |
| Zip | 27,701 |